Achillion Pharmaceuticals and J&J Were Slightly Down in Premarket Trading After the Discontinuation of Further Hepatitis C Treatment Investigation Was Announced

12 September 2017 12:30

Johnson & Johnson with Achillion Pharmaceuticals were down slightly at more than 20 percent in premarket trading after the announcement of Janssen Sciences Ireland about the discontinuation of further development of hepatitis C treatment investigation. The Janssen authorities comment on that it was a strategic decision because of the number of brand new therapy for hepatitis C, and the number increases rapidly.

"Going forward, our hepatitis R&D efforts will focus on chronic hepatitis B, where a high unmet medical need still exists," comment on  Lawrence Blatt, global therapeutic area head, infectious disease therapeutics, Janssen.


Share with Telegram

Latest News

New Findings Shed Light on How HIV-Blocking Antibodies are Generated

New data illuminate how some human beings generate powerful, HIV-blocking antibodies. The results offer important insight into a potential AIDS vaccine design.

23 November 13:36

HIV-Positive Are Under-Treated for Cardiovascular Problems

People with both HIV and risk factors for heart disease and stroke were less likely to be treated with cholesterol-lowering statin drugs and aspirin than patients without HIV.

23 November 10:35

“Digital bathhouses”: Health experts see dating apps as the new frontier for STD

“Because these are closed pools of people in limited geographies using dating apps, it means that infections can spread more easily,” said Michael Weinstein, the president of the AIDS Healthcare Foundation. “That’s why we call apps a ‘digital bathhouse’.”

22 November 15:37

FDA approves first two-drug regimen for patients with HIV-1

FDA approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 (HIV-1).

22 November 08:10